Q-omics provides the consensus-scored ADNP2 profile across patient tissues and cancer cell-line models. ADNP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ADNP2 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, ADNP2 protein abundance shows 20,591 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, LIHC, and GBM as cancer lineages where ADNP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADNP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADNP2 survival associations across molecular data types. ADNP2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADNP2 RNA expression–survival associations across cancer types. High ADNP2 expression shows unfavorable associations in MESO, ACC, BLCA, THCA and UVM, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ADNP2 RNA expression.
This table summarizes ADNP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ADNP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADNP2 shows lower tumor expression in THCA and higher tumor expression in LIHC, BRCA, CHOL, LUSC and STAD. The LIHC box plot shows higher ADNP2 RNA expression in tumor versus normal tissue (log2 FC = +0.996, t-test p < 0.001).
This table shows molecular features associated with ADNP2 in patient tissues and cancer cell lines. In patient samples, ADNP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADNP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
